Secures $50M Revolving Credit Facility from Largest Shareholder's Affiliate with High Costs and Future Concessions

summarizeSummary

TuHURA Biosciences secured a $50 million revolving credit facility from an affiliate of its largest stockholder, extending its cash runway but at a high cost including a 12% interest rate, asset-backed security, a royalty on its key IFx-2.0 product, and significant potential dilution from an equity commitment fee and warrant extensions.

check_boxKey Events · Financing and Capital Events · HURA

• Secures $50 Million Revolving Credit Facility

  TuHURA Biosciences entered into a Loan Agreement with Parkview Holdings One LLC, an affiliate of its largest stockholder, for a $50 million revolving credit facility maturing on April 21, 2031. This facility is expected to fund operations and development programs into Q1 2028, addressing the company's 'going concern' warning.

• High Cost of Capital and Secured Assets

  The credit facility bears a high annual interest rate of 12% (plus an additional 6% upon default) and is secured by substantially all of the company's assets, limiting future financial flexibility.

• Significant Equity Commitment Fee

  The company has elected to pay a one-time $5.0 million loan commitment fee by issuing 1,878,287 shares of common stock to Parkview (valued at $2.662 per share), contingent on stockholder approval. If not approved by August 31, 2026, the fee becomes payable in cash.

• Royalty Granted on Key Product IFx-2.0

  TuHURA granted Parkview an annual royalty in the low to mid-single digits percentage on sales of products incorporating IFx-2.0, up to $450 million in net sales per year, for the life of the patent.

auto_awesomeAnalysis · HURA · Life Sciences

This 8-K filing is highly important as it addresses TuHURA Biosciences' critical need for capital, previously highlighted by a 'going concern' warning. The $50 million revolving credit facility provides a crucial lifeline, extending the company's cash runway into the first quarter of 2028. However, the financing comes with substantial costs and concessions, reflecting the company's challenging financial position. The high 12% interest rate, the facility being secured by substantially all company assets, and the grant of a low to mid-single digit royalty on future sales of its key IFx-2.0 product will significantly impact future profitability and financial flexibility. Furthermore, the commitment to issue 1,878,287 shares for a $5.0 million fee (subject to stockholder approval) and the extension of over 4.3 million warrants held by the lender's affiliate represent considerable potential dilution for existing shareholders. The involvement of an affiliate of the largest stockholder suggests that securing capital from other sources may have been difficult, underscoring the company's precarious financial state despite this new funding.